Show simple item record

dc.contributor.authorLienlaf, M.
dc.contributor.authorPerez-Villarroel, P.
dc.contributor.authorKnox, T.
dc.contributor.authorPabon, M.
dc.contributor.authorSahakian, E.
dc.contributor.authorPowers, J.
dc.contributor.authorWoan, K.V.
dc.contributor.authorLee, C.
dc.contributor.authorCheng, F.
dc.contributor.authorDeng, S.
dc.contributor.authorSmalley, K.S.M.
dc.contributor.authorMontecino, M.
dc.contributor.authorKozikowski, A.
dc.contributor.authorPinilla-Ibarz, J.
dc.contributor.authorSarnaik, A.
dc.contributor.authorSeto, E.
dc.contributor.authorWeber, J.
dc.contributor.authorSotomayor, E.M.
dc.contributor.authorVillagra, A.
dc.date.accessioned2017-07-24T15:38:15Z
dc.date.available2017-07-24T15:38:15Z
dc.date.issued2016-05
dc.identifier.citationMolecular Oncology Volume 10, Issue 5, 1 May 2016, Pages 735-750es_CL
dc.identifier.issn1574-7891
dc.identifier.otherDOI: 10.1016/j.molonc.2015.12.012
dc.identifier.urihttp://repositorio.unab.cl/xmlui/handle/ria/3764
dc.descriptionIndexación: Web of Science; Scopus.es_CL
dc.description.abstractHistone deacetylases (HDACs), originally described as histone modifiers, have more recently been deMonstrated to target a variety of other proteins unrelated to the chromatin environment. In this context, our present work demonstrates that the pharmacological or genetic abrogation of HDAC6 in primary melanoma samples and cell lines, down-regulates the expression of PD-L1, an important co-stimulatory molecule expressed in cancer cells, which activates the inhibitory regulatory pathway PD-1 in T-cells. Our data suggests that this novel mechanism of PD-L1 regulation is mainly mediated by the influence of HDAC6 over the recruitment and activation of STAT3. Additionally, we observed that selective HDAC6 inhibitors impairs tumor growth and reduce the in vim expression of several inhibitory checkpoint molecules and other regulatory pathways involved in immunosurveillance. Most importantly, these results provide a key pre-clinical rationale and justification to further study isotype selective HDAC6 inhibitors as potential immuno-modulatory agents in cancer. (C) 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.es_CL
dc.description.urihttp://onlinelibrary.wiley.com/doi/10.1016/j.molonc.2015.12.012/abstract;jsessionid=DB86CF943DA7FD358A75C2CEEAD4D7C4.f03t01
dc.language.isoenes_CL
dc.publisherELSEVIER SCIENCEes_CL
dc.subjectHistone deacetylaseses_CL
dc.subjectHDAC6es_CL
dc.subjectPD-L1es_CL
dc.subjectSTAT3es_CL
dc.subjectPP2Aes_CL
dc.subjectMelanomaes_CL
dc.subjectNexturastates_CL
dc.subjectTubastatin Aes_CL
dc.titleEssential role of HDAC6 in the regulation of PD-L1 in melanomaes_CL
dc.typeArticlees_CL


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record